We carried out these analyses in a global population enrolled in the prospective comparison of angiotensin receptor-neprilysin inhibitor with angiotensin-converting enzyme inhibitor (ACE-i) to determine impact on global mortality and morbidity in heart failure trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure [PARADIGM-HF]) which included 1832 women and 6567 men with HFrEF enrolled in 47 countries on six continents.35 The gene discussed is ACE; the disease is heart failure.